A metabolic “switch” that could help reset scar-producing cells in scleroderma

Blocking the enzyme NNMT points toward a new approach to treating fibrosis

11:00 AM

Author | Valerie Goodwin

scratching arm pink sweater in living room teal couch
Getty Images

Researchers at University of Michigan Health and collaborating institutions have identified a metabolic enzyme that may offer a fundamentally new way to attack one of the most difficult-to-treat features of systemic sclerosis, or scleroderma: progressive and potentially life threatening tissue scarring.

Despite decades of research and numerous clinical trials, effective treatment of scleroderma fibrosis remains a major unmet need.

Currently available therapies have limited ability to produce durable control of the fibrosis that can damage the skin, lungs and other internal organs.

In a new study published in the Journal of Investigative Dermatology, investigators identify nicotinamide N-methyltransferase, or NNMT, as a key regulator of the abnormal metabolic and epigenetic programming that can keep fibroblasts “locked” into a persistently activated, scar-producing state.

The researchers tested a novel small-molecule NNMT inhibitor in fibroblasts from patients with systemic sclerosis and in a mouse model of skin fibrosis.

Inhibiting NNMT suppressed the transformation of fibroblasts into scar-producing myofibroblasts and reduced excessive production of collagen and other extracellular matrix components.

Importantly, NNMT inhibition also corrected metabolic abnormalities associated with the fibrotic state, including alterations in NAD⁺ homeostasis and cellular methylation balance.

In mice, inhibitor treatment reduced pathological skin thickening and collagen accumulation, preventing loss of the normal fat layer beneath the skin.

The study suggests a potentially important shift in how fibrosis might be treated.

SEE ALSO: Pain, psychological factors and physical function closely linked in people with systemic sclerosis

Rather than simply blocking one of the many signals that stimulate collagen production, targeting NNMT may help “reset” the fibrotic cell itself by correcting the abnormal metabolic and epigenetic program that sustains its scar-producing behavior.

“Fibroblasts in scleroderma acquire a kind of cellular memory that keeps them producing scar tissue even when the original stimulus is no longer present,” said senior author John Varga, M.D., Chief of Rheumatology at U-M Health.

“Our findings suggest that targeting NNMT activity provides a way to reset that cellular memory—restoring a more normal metabolic and epigenetic state rather than simply blocking an individual fibrotic signal.”

The study establishes NNMT as a previously underappreciated connection between cellular metabolism, epigenetic regulation and fibrosis.

SEE ALSO: For scleroderma research, patients seen as essential co-creators

The findings also raise the possibility that NNMT and its associated metabolic signature could eventually help researchers better define or stage fibrotic disease and identify patients most likely to benefit from targeted treatment.

“Ultimately, the work opens an exciting new avenue toward therapies designed not simply to slow scar formation, but potentially to reprogram the cells responsible for fibrosis toward a healthier state,” said Varga.

“Further research will be needed to determine whether NNMT inhibition can be translated safely and effectively into treatment for people with systemic sclerosis and other fibrotic diseases.”

Additional authors: Kamal Saba, Sunny Kataria, Umesh Kumar, Prihanka Verma, John Keyokgy, Gabriel Walters, Pei-Suen Tsou and M Astif Amin from the Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA. Bo Shi from the Department of Dermatology, Northwestern University, Chicago, IL USA. Claudia C S Chini and Eduardo N Chini from the Metabolism and Molecular Nutrition Laboratory, Kogod Center on Aging, Department of Anaesthesiology and Perioperative Medicine, Mayo Clinic College of Medicine, Jacksonville, FL, USA. Tianqi Zhao and Rong Huang from the Borch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN USA. Iredia D Iyamu from the Borch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN USA and the Department of Medicinal Chemistry, University of Kansas, Lawrence, KS USA.

Paper cited: “A Bisubstrate Inhibitor of NNMT Suppresses Myofibroblast Reprogramming to Mitigate Skin Fibrosis,” Journal of Investigative Dermatology. DOI: 10.1016/j.jid.2026.07.037

Sign up for Health Lab newsletters today. Get medical tips from top experts and learn about new scientific discoveries every week

Sign up for the Health Lab Podcast. Add us wherever you listen to your favorite shows


More Articles About:

Rheumatology Skin Conditions All Research Topics Scars
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

In This Story

portrait of John Varga

John Varga, MD, FACP, MACR

Professor

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

Alarm clock sitting on a white dinner plate with blue and yellow flowers on the rim and a fork and knife positioned on either side of the plate.
Health Lab

Intermittent fasting can reverse diabetes in mice, study finds

Study shows intermittent fasting and meal timing can help reverse type 2 diabetes by resting pancreatic beta cells
Mother sits on a couch with a laptop on her lap while an elementary school age boy sits next to her playing on a tablet device.
Health Lab

New questionnaire aims to improve understanding of demand avoidance in children, teens

Pathological demand avoidance is a pattern of intense distress and avoidance of demands in children. A new questionnaire from University of Michigan researchers creates a structured way to assess these behaviors.
Blue round cells in three pictures showing how they change under stress.
Health Lab

Timing is of the essence for RNA during stress

Key determiners of which RNA can be read to make proteins is time. Previous thinking was that a cell under threat would quickly make these RNAs in the nucleus and immediately push them into the cytoplasm.
Blue and yellow illustration of DNA helix
Health Lab

New anti-cancer strategy shows promise in preclinical studies

New cancer therapeutic strategy rewires protein interactions to improve efficacy and reduce potential side effects.
Closeup of newborn baby, whose head is held by a blue medical gloved hand. Blue gloved hand also holds a stethoscope to baby's chest.
Health Lab

More babies with hypoplastic left heart syndrome surviving critical period between surgeries

Collaborative effort helped sustain improvements in survival for babies born with hypoplastic left heart syndrome (HLHS), a serious congenital heart condition that requires multiple surgeries.
Rachel Upjohn Building groundbreaking ceremony
News Release

How U-M helped bring depression out of the darkness

The history of the founding of the Eisenberg Family Depression Center at the University of Michigan, the nation's first center focused on research, community outreach and stigma reduction in depression and bipolar disorder.